JP2024546654A5 - - Google Patents
Info
- Publication number
- JP2024546654A5 JP2024546654A5 JP2024533810A JP2024533810A JP2024546654A5 JP 2024546654 A5 JP2024546654 A5 JP 2024546654A5 JP 2024533810 A JP2024533810 A JP 2024533810A JP 2024533810 A JP2024533810 A JP 2024533810A JP 2024546654 A5 JP2024546654 A5 JP 2024546654A5
- Authority
- JP
- Japan
- Prior art keywords
- syndrome
- disease
- cancer
- autoimmune
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288330P | 2021-12-10 | 2021-12-10 | |
| US63/288,330 | 2021-12-10 | ||
| PCT/US2022/081186 WO2023108073A2 (en) | 2021-12-10 | 2022-12-08 | Polypeptide modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546654A JP2024546654A (ja) | 2024-12-26 |
| JP2024546654A5 true JP2024546654A5 (cg-RX-API-DMAC7.html) | 2025-12-16 |
Family
ID=86731448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533810A Pending JP2024546654A (ja) | 2021-12-10 | 2022-12-08 | ポリペプチドモジュレーター |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250051419A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4444339A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024546654A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240118832A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118613277A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022405109A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3241913A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313360A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024006897A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023108073A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026519808A (ja) * | 2023-06-06 | 2026-06-18 | ジョージアミューン・インコーポレイテッド | 新規pd-l2変異体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002000692A2 (en) * | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US10260038B2 (en) * | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| CN106794235A (zh) * | 2014-07-18 | 2017-05-31 | 阿德瓦希斯公司 | 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物 |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| US11219694B2 (en) * | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| CN118085109A (zh) * | 2016-08-11 | 2024-05-28 | 昆士兰医学研究所理事会 | 免疫调节化合物 |
| JP2020511144A (ja) * | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| WO2019060888A1 (en) * | 2017-09-25 | 2019-03-28 | New York University | HETÉRODIMÈRE-FC FUSION PROTEINS |
| US20210213063A1 (en) * | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3908600A1 (en) * | 2019-01-11 | 2021-11-17 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Fusion protein with immunosuppressive activity |
-
2022
- 2022-12-08 MX MX2024006897A patent/MX2024006897A/es unknown
- 2022-12-08 WO PCT/US2022/081186 patent/WO2023108073A2/en not_active Ceased
- 2022-12-08 CA CA3241913A patent/CA3241913A1/en active Pending
- 2022-12-08 IL IL313360A patent/IL313360A/en unknown
- 2022-12-08 KR KR1020247022359A patent/KR20240118832A/ko active Pending
- 2022-12-08 JP JP2024533810A patent/JP2024546654A/ja active Pending
- 2022-12-08 US US18/718,397 patent/US20250051419A1/en active Pending
- 2022-12-08 EP EP22905373.1A patent/EP4444339A4/en active Pending
- 2022-12-08 AU AU2022405109A patent/AU2022405109A1/en active Pending
- 2022-12-08 CN CN202280090526.6A patent/CN118613277A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2948647T3 (es) | Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas | |
| ES3058927T3 (en) | Cell-penetrating peptide conjugates and methods of their use | |
| JP2010518006A5 (cg-RX-API-DMAC7.html) | ||
| JP7564087B2 (ja) | アンチセンス送達のための三量体ペプチド | |
| JP2025032075A (ja) | Baff-r二重特異性t細胞エンゲージャー抗体 | |
| JP2020513855A5 (cg-RX-API-DMAC7.html) | ||
| RU2009114161A (ru) | Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника | |
| CN113905744A (zh) | 经修饰的间隙子寡核苷酸及其使用方法 | |
| JP2002505309A (ja) | 腫瘍治療のための組成物および方法 | |
| EP3271395A1 (en) | Single-chain tnf ligand family molecules and fusion proteins and derivatives thereof | |
| ES2401822T3 (es) | Utilización de imidazoquinolinas para el tratamiento de enfermedades dependientes de EGFR o enfermedades que han adquirido resistencia a agentes que tienen como objetivo mienbros de la familia de EGFR | |
| AU2024259837B2 (en) | ADP-ribose binding peptide having anticancer activity and use thereof | |
| CN102633883A (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| CN121943909A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| ES2277683T3 (es) | Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico. | |
| WO2023196876A1 (en) | Il-7ralpha-gamma ligand immunoglobulin fusion proteins | |
| WO2020041691A9 (en) | Oligonucleotide inhibitors of nuclear factor kappa-light-chain-enhancer of activated b cells and uses thereof | |
| CN120437288A (zh) | 治疗卵巢癌的药物组合 | |
| JP2025515191A5 (cg-RX-API-DMAC7.html) | ||
| JP2024542096A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment | |
| AU2022341787A1 (en) | Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy | |
| WO2025087363A1 (zh) | 用TACI-Fc融合蛋白治疗自身免疫性脑炎的方法 | |
| JP2024546654A (ja) | ポリペプチドモジュレーター | |
| US12043673B2 (en) | Complementary RNA linked bispecific T-cell engaging antibodies |